Publications by authors named "P Jhingran"
Background: The coexistence of transthyretin cardiac amyloidosis (ATTR-CA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. We aimed to characterize clinical outcomes in AS plus ATTR-CA compared with only AS or ATTR-CA.
Methods And Results: In a retrospective cohort study, patients with AS only, ATTR-CA only, or AS plus ATTR-CA were identified using all-payer claims data (2015-2021).
Objective: To describe adherence to daily somatropin treatment and impact on height velocity within 1 year of treatment start among patients with pediatric growth hormone deficiency in a real-world US population.
Methods: This retrospective cohort study included pediatric patients aged ≥3 years to <16 years with pediatric growth hormone deficiency prescribed somatropin by a pediatric endocrinologist at a US-based center of excellence between January 1, 2015 and December 31, 2020. Patient data were collected using hospital electronic health records linked to a specialty pharmacy patient prescription records.
This study explored the perceived value of real-world evidence (RWE) in the reassessment of oncology therapies by collecting the perspectives of health technology assessment/payer decision-makers. A web-based survey was conducted using the Market Access Transformation Rapid Payer Response online portal. 30 participants from France, Germany, Spain, the UK and the USA were recruited based on their expertise.
View Article and Find Full Text PDFPersistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK.
Front Endocrinol (Lausanne)
November 2022
Background: Children with growth hormone deficiency (GHD) are treated with daily somatropin injections; however, poor treatment persistence and adherence have been recognized previously and have been shown to negatively impact growth outcomes. A recent real-world study of a US pediatric GHD population found that a substantial proportion of children discontinued somatropin therapy, but similar data for a real-world UK population are lacking.
Objectives: To describe the discontinuation of, and persistence with, daily somatropin treatment among children with GHD in the UK.
Article Synopsis
- The study aimed to examine how well children with pediatric growth hormone deficiency (pGHD) adhered to treatment with somatropin over three years and the reasons for any discontinuation.
- It involved children aged 3 to 16 covered by Medicaid, analyzing data based on prescription fills from July 2014 to December 2018, defining adherence as a medication possession ratio and discontinuation as gaps between prescriptions.
- Results indicated that over time, adherence declined (from 40.9% to 54.4% suboptimal adherence), with certain sociodemographic factors, such as age and race, influencing adherence and discontinuation rates, highlighting the need for targeted interventions.